Morningstar

Accord BioPharma Announces Commercial Launch of IMULDOSA® (ustekinumab-srlf) Prefilled Syringes at Lowest WAC Price Among Branded Biosimilars to STELARA® (ustekinumab)

RALEIGH, N.C., Aug. 18, 2025 /PRNewswire/ -- Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology ...
Drug Store News

Biocon Biologics secures market access coverage for Stelara biosimilar

Biocon Biologics has secured multiple market access agreements for Yesintek (ustekinumab-kfce), its biosimilar to Stelara (ustekinumab). The market access agreements from numerous plans represent more ...
Nasdaq

Teva Pharmaceuticals and Alvotech Announce FDA Approval of SELARSDI™ Biosimilar for Multiple Indications

In October 2024, the FDA approved the biosimilar SELARSDI™ (ustekinumab-aekn), manufactured by Teva Pharmaceuticals in partnership with Alvotech, for various conditions similar to those treated by the ...
MarketWatch

Accord BioPharma Announces Commercial Launch of IMULDOSA(R) (ustekinumab-srlf) Prefilled Syringes at Lowest WAC Price Among Branded Biosimilars to STELARA(R) (ustekinumab)

The MarketWatch News Department was not involved in the creation of this content. Company's third biosimilar expands access to proven targeted biologic therapy with patient-centric support services ...